Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rituximab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TREatment of degeNerative and Neoplastic Diseases With Rituximab
Details : Rituximab is a Antibody drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 14, 2011
Lead Product(s) : Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
